CTVA · 10-Q · 2026Q4 · Full report

Operating Cash Flow Trends

Corteva, Inc. · 2026-11-12 · Importance 77 · Surprise 82 · From source text

Cash used for operating activities from continuing operations was $3.878 billion for the nine months ended September 30, 2026, versus $941 million in the comparable 2025 period. The $2.937 billion increase in cash use was driven by a discretionary pension contribution, the Bayer resolution payment, higher compensation payments and the FMC rimisoxafen prepayment. Improved collections partially offset those outflows. Cash used for discontinued operations was $70 million, compared with $28 million in the prior-year period, primarily related to insurance proceeds and PFAS remediation and litigation matters.

Key facts

• Corteva's operating activities in continuing operations used $3,878 million in the first nine months of 2026, compared with $941 million in the first nine months of 2025. source
• Discontinued-operations operating cash outflows were $70 million in the first nine months of 2026, compared with $28 million in the first nine months of 2025. source
• The year-over-year change in continuing operating cash flow was driven by the discretionary pension contribution, Bayer resolution payment, higher compensation payments, and FMC rimisoxafen prepayment, partially offset by improved collections. source

Impact estimates